相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting p53 for the treatment of cancer
Michael J. Duffy et al.
SEMINARS IN CANCER BIOLOGY (2022)
A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells
Jayoung Song et al.
CANCER LETTERS (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study
Karen Yee et al.
LEUKEMIA RESEARCH (2021)
Mutant p53 as a Regulator and Target of Autophagy
Yong Shi et al.
FRONTIERS IN ONCOLOGY (2021)
Adamantyl Isothiocyanates as Mutant p53 Rescuing Agents and Their Structure-Activity Relationships
Vladimir Burmistrov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
Sebastian Bauer et al.
BRITISH JOURNAL OF CANCER (2021)
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N. Saleh et al.
CLINICAL CANCER RESEARCH (2021)
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoine Italiano et al.
INVESTIGATIONAL NEW DRUGS (2021)
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
Seyed Pairawan et al.
BREAST CANCER RESEARCH (2021)
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
Naoise C. Synnott et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Musaffe Tuna et al.
BRITISH JOURNAL OF CANCER (2020)
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
Albiruni R. Abdul Razak et al.
INVESTIGATIONAL NEW DRUGS (2020)
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
Geoffrey L. Uy et al.
INVESTIGATIONAL NEW DRUGS (2020)
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Chenggong Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
John D. Martin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
David S. Hong et al.
BRITISH JOURNAL OF CANCER (2020)
Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA
Jonathan L. S. Esguerra et al.
MOLECULAR METABOLISM (2020)
Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming
Jia Liu et al.
NATURE COMMUNICATIONS (2020)
The Impact of Mutant p53 in the Non-Coding RNA World
Silvia Di Agostino
BIOMOLECULES (2020)
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2020)
MDM2 inhibition: an important step forward in cancer therapy
Marina Konopleva et al.
LEUKEMIA (2020)
Tumorigenic p53 mutants undergo common structural disruptions including conversion toα-sheetstructure
Dennis Bromley et al.
PROTEIN SCIENCE (2020)
Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome
Valeria Capaci et al.
NATURE COMMUNICATIONS (2020)
The P53/microRNA network: A potential tumor suppressor with a role in anticancer therapy
Javad Sargolzaei et al.
PHARMACOLOGICAL RESEARCH (2020)
LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer
Xiangfeng Meng et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Microchip-Based Structure Determination of Disease-Relevant p53
Maria J. Solares et al.
ANALYTICAL CHEMISTRY (2020)
Mutant p53 in Cancer Progression and Targeted Therapies
Gaoyang Zhu et al.
FRONTIERS IN ONCOLOGY (2020)
The miR-34 family and its clinical significance in ovarian cancer
Hannah Welponer et al.
JOURNAL OF CANCER (2020)
MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop
Peng Luo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma
Shufang Jin et al.
MOLECULAR CANCER (2019)
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors
Zsuzsanna Papai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
Arushi Khurana et al.
ONCOTARGETS AND THERAPY (2019)
Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression
Gabriella D'Orazi et al.
CANCERS (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar et al.
CLINICAL CANCER RESEARCH (2019)
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
Yao Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs
Yuechao Zhao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The biogenesis, biology and characterization of circular RNAs
Lasse S. Kristensen et al.
NATURE REVIEWS GENETICS (2019)
The Role of Non-coding RNAs in Oncology
Frank J. Slack et al.
CELL (2019)
A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C
Matthias R. Bauer et al.
FUTURE MEDICINAL CHEMISTRY (2019)
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
Douglas D. Fang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Harry P. Erba et al.
BLOOD ADVANCES (2019)
Mutant p53 increases exosome-mediated transfer of miR-21-3p and miR-769-3p to promote pulmonary metastasis
Qiang Ju et al.
CHINESE JOURNAL OF CANCER RESEARCH (2019)
Mutant p53 in cancer therapy-the barrier or the path
Xiang Zhou et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Kanaga Sabapathy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
A mitosis-specific and R loop-driven ATR pathway promotes faithful chromosome segregation
Lilian Kabeche et al.
SCIENCE (2018)
Functional Classification and Experimental Dissection of Long Noncoding RNAs
Florian Kopp et al.
CELL (2018)
Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1
Ling Fang et al.
CELL DEATH AND DIFFERENTIATION (2018)
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
Eduardo Mendez et al.
CLINICAL CANCER RESEARCH (2018)
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Anish Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation
Eran Kotler et al.
MOLECULAR CELL (2018)
ATR/CHK1 inhibitors and cancer therapy
Zhaojun Qiu et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Luis A. Carvajal et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus
Jack D. Godfrey et al.
CELL DEATH & DISEASE (2018)
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Tomer Cooks et al.
NATURE COMMUNICATIONS (2018)
Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma
Silvia Di Agostino et al.
THERANOSTICS (2018)
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Ramona Schulz-Heddergott et al.
CANCERS (2018)
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201
Sebastien Jeay et al.
CANCER RESEARCH (2018)
Long non-coding RNA: its evolutionary relics and biological implications in mammals: a review
Jasdeep Kaur Dhanoa et al.
JOURNAL OF ANIMAL SCIENCE AND TECHNOLOGY (2018)
The interplay between mutant p53 and the mevalonate pathway
Alejandro Parrales et al.
CELL DEATH AND DIFFERENTIATION (2018)
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov et al.
NATURE REVIEWS CANCER (2018)
Autophagy pathway: Cellular and molecular mechanisms
Li Yu et al.
AUTOPHAGY (2018)
Non-coding RNAs as drug targets
Masayuki Matsui et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Long noncoding RNAs in the p53 network
Ritu Chaudhary et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2017)
Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism
Matilda Eriksson et al.
MOLECULAR AND CELLULAR BIOLOGY (2017)
Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases
Matthias Schmidt et al.
MOLECULES (2017)
Synthetic lethality and cancer
Nigel J. O'Neil et al.
NATURE REVIEWS GENETICS (2017)
The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex
Lorena Verduci et al.
GENOME BIOLOGY (2017)
Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer
Dariusz Waniczek et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1
Magdalena Pruszko et al.
EMBO REPORTS (2017)
miR-34a and miR-34b/c Suppress Intestinal Tumorigenesis
Longchang Jiang et al.
CANCER RESEARCH (2017)
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff et al.
CLINICAL CANCER RESEARCH (2016)
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Andreas C. Joerger et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 85 (2016)
The Roles of MDM2 and MDMX in Cancer
Orit Karni-Schmidt et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Alice Soragni et al.
CANCER CELL (2016)
Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
Huanan Wang et al.
CANCER CELL INTERNATIONAL (2016)
Xist and Tsix Transcription Dynamics Is Regulated by the X-to-Autosome Ratio and Semistable Transcriptional States
Friedemann Loos et al.
MOLECULAR AND CELLULAR BIOLOGY (2016)
Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value
Didier Meseure et al.
MOLECULAR CANCER RESEARCH (2016)
Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
Marco Cordani et al.
MOLECULAR ONCOLOGY (2016)
Unique features of long non-coding RNA biogenesis and function
Jeffrey J. Quinn et al.
NATURE REVIEWS GENETICS (2016)
NON-CODING RNAs IN DEVELOPMENT AND DISEASE: BACKGROUND, MECHANISMS, AND THERAPEUTIC APPROACHES
Julia Beermann et al.
PHYSIOLOGICAL REVIEWS (2016)
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
Matthias R. Bauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells
Francesca Grespi et al.
CELL DEATH & DISEASE (2016)
LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern
Tian-Tian Sun et al.
CANCER DISCOVERY (2016)
The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Jiandong Chen
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Jonathan D. Oliner et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors
Amita Patnaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53
Shengliang Zhang et al.
CANCER RESEARCH (2015)
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
Masatsugu Hiraki et al.
CHEMISTRY & BIOLOGY (2015)
p53-dependent non-coding RNA networks in chronic lymphocytic leukemia
C. J. Blume et al.
LEUKEMIA (2015)
p53 in survival, death and metabolic health: a lifeguard with a licence to kill
Flore Kruiswijk et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Targeting Oncogenic Mutant p53 for Cancer Therapy
Alejandro Parrales et al.
FRONTIERS IN ONCOLOGY (2015)
An update on LNCipedia: a database for annotated human lncRNA sequences
Pieter-Jan Volders et al.
NUCLEIC ACIDS RESEARCH (2015)
A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis
M. Subramanian et al.
ONCOGENE (2015)
Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore
Adam R. Blanden et al.
MOLECULAR PHARMACOLOGY (2015)
Targeting of miR34a-NOTCH1 Axis Reduced Breast Cancer Stemness and Chemoresistance
Eun Young Park et al.
CANCER RESEARCH (2014)
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Susann Weissmueller et al.
CELL (2014)
The ENCODE Project and Perspectives on Pathways
Vinicius Tragante et al.
GENETIC EPIDEMIOLOGY (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Development of Synthetic Lethality Anticancer Therapeutics
Bingliang Fang
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Polo-like kinases: structural variations lead to multiple functions
Sihem Zitouni et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Applying Synthetic Lethality for the Selective Targeting of Cancer
Donal P. McLornan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells
S. Masciarelli et al.
ONCOGENE (2014)
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53
Shunbin Xiong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer Growth
Lei Wang et al.
CELL REPORTS (2014)
Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells
Ameya Paranjpe et al.
CARCINOGENESIS (2013)
Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors
Brooke M. Emerling et al.
CELL (2013)
Chaperone-mediated autophagy degrades mutant p53
Helin Vakifahmetoglu-Norberg et al.
GENES & DEVELOPMENT (2013)
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53
Xiangbing Meng et al.
GYNECOLOGIC ONCOLOGY (2013)
RCP-driven α5β1 recycling suppresses Rac and promotes RhoA activity via the RacGAP1-IQGAP1 complex
Guillaume Jacquemet et al.
JOURNAL OF CELL BIOLOGY (2013)
Progress in microRNA delivery
Yu Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2013)
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study
Julie M. Vose et al.
LEUKEMIA & LYMPHOMA (2013)
Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence
Hongmei Luo et al.
LUNG CANCER (2013)
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
W. Yan et al.
ONCOGENE (2013)
Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination
M. Krajewska et al.
ONCOGENE (2013)
Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis
P. Dong et al.
ONCOGENE (2013)
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
X. Peng et al.
CELL DEATH & DISEASE (2013)
The p53 miRNA interactome and its potential role in the cancer clinic
Jonathan Krell et al.
EPIGENOMICS (2013)
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Christopher D. Wassman et al.
NATURE COMMUNICATIONS (2013)
Tumour-associated mutant p53 drives the Warburg effect
Cen Zhang et al.
NATURE COMMUNICATIONS (2013)
miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma
Andrea L. Kasinski et al.
CANCER RESEARCH (2012)
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
William H. Chappell et al.
CELL CYCLE (2012)
GENCODE: The reference human genome annotation for The ENCODE Project
Jennifer Harrow et al.
GENOME RESEARCH (2012)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death
C. Wanka et al.
ONCOGENE (2012)
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Bradford Graves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Secreted microRNAs: a new form of intercellular communication
Xi Chen et al.
TRENDS IN CELL BIOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Kathleen A. Bridges et al.
CLINICAL CANCER RESEARCH (2011)
Gambogic Acid-Induced Degradation of Mutant p53 is Mediated by Proteasome and Related to CHIP
Jia Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1
Jonathon D. Roybal et al.
MOLECULAR CANCER RESEARCH (2011)
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Philip M. Reaper et al.
NATURE CHEMICAL BIOLOGY (2011)
Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors
A. V. Vaseva et al.
CELL DEATH & DISEASE (2011)
Regulation of mRNA Translation and Stability by microRNAs
Marc Robert Fabian et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 79 (2010)
Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells
Issam Ben Sahra et al.
CANCER RESEARCH (2010)
SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53
Mark Demma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells
Laureline Roger et al.
JOURNAL OF CELL SCIENCE (2010)
Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of p53 Wild-Type Cancer Cells
Diarmuid M. Moran et al.
MOLECULAR CANCER THERAPEUTICS (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Sanjeev Shangary et al.
Annual Review of Pharmacology and Toxicology (2008)
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
L. Weinmann et al.
CELL DEATH AND DIFFERENTIATION (2008)
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
Tamara Terzian et al.
GENES & DEVELOPMENT (2008)
Mutant p53 targeting by the low molecular weight compound STIMA-1
Nicole Zache et al.
MOLECULAR ONCOLOGY (2008)
P53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Keiko Kawauchi et al.
NATURE CELL BIOLOGY (2008)
ATR: an essential regulator of genome integrity
Karlene A. Cimprich et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
J. E. Kravchenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Frank M. Boeckler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells
K. Lin et al.
ONCOGENE (2008)
DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant p53-determined p16ink4A down-regulation
Zhanjun Guo et al.
JOURNAL OF BIOMEDICAL SCIENCE (2008)
Differential regulation of microRNAs by p53 revealed by massively parallel Sequencing -: miR-34a is a p53 target that induces apoptosis and G1-arrest
Valery Tarasov et al.
CELL CYCLE (2007)
Structure-function-rescue: the diverse nature of common p53 cancer mutants
A. C. Joerger et al.
ONCOGENE (2007)
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
H. Christian Reinhardt et al.
CANCER CELL (2007)
Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
J-C Marine et al.
CELL DEATH AND DIFFERENTIATION (2006)
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
VJN Bykov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression
F Schwartzenberg-Bar-Yoseph et al.
CANCER RESEARCH (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
N Issaeva et al.
NATURE MEDICINE (2004)
AIF deficiency compromises oxidative phosphorylation
N Vahsen et al.
EMBO JOURNAL (2004)
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints
A Sancar et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
A peptide that binds and stabilizes p53 core domain:: Chaperone strategy for rescue of oncogenic mutants
A Friedler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1
S North et al.
MOLECULAR CARCINOGENESIS (2002)
Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations
PV Nikolova et al.
EMBO JOURNAL (2000)
分享论文
